Australia markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.18+0.02 (+0.32%)
At close: 04:00PM EDT
6.00 -0.18 (-2.91%)
After hours: 05:07PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 115.27M
Enterprise value 97.16M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.20
Enterprise value/revenue N/A
Enterprise value/EBITDA -7.38

Trading information

Stock price history

Beta (5Y monthly) 0.46
52-week change 3-54.92%
S&P500 52-week change 320.52%
52-week high 314.96
52-week low 35.85
50-day moving average 36.61
200-day moving average 37.49

Share statistics

Avg vol (3-month) 397.28k
Avg vol (10-day) 3106.89k
Shares outstanding 518.65M
Implied shares outstanding 618.65M
Float 86.64M
% held by insiders 153.26%
% held by institutions 111.44%
Shares short (15 Aug 2024) 4902.52k
Short ratio (15 Aug 2024) 418.01
Short % of float (15 Aug 2024) 49.51%
Short % of shares outstanding (15 Aug 2024) 44.84%
Shares short (prior month 15 July 2024) 4884.19k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-60.89%
Return on equity (ttm)-128.44%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-21.1M
Diluted EPS (ttm)-1.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)18.12M
Total cash per share (mrq)0.97
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.17
Book value per share (mrq)0.67

Cash flow statement

Operating cash flow (ttm)-14.47M
Levered free cash flow (ttm)-6.93M